Reconstruction of Bilateral Upper Extremity High-Voltage Electrical Injuries.

Hand ClinJul 30, 2026 (epub)
Case ReportPlastic SurgeryGeneral Surgery

S Raja Sabapathy, R Raja Shanmugakrishnan, Shruthi Chandrasekar

✦ AI-curated · Sources linked

Case in brief

A young boy presented with high-voltage electrical injuries resulting in significant tissue loss in both upper limbs, particularly affecting the fingers and the volar aspect of the wrist. The reconstructive approach involved careful debridement and strategic soft tissue coverage to address the complex nature of the injuries. The case highlights the importance of timing and technique in achieving functional restoration.

Diagnostic / clinical pearl

Reconstructive surgeons must carefully assess the extent of tissue loss in high-voltage electrical injuries to determine the appropriate timing and method for debridement and soft tissue coverage.

Source

PubMed · PMID 42816017

Published in Hand Clin. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Plastic Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.